1. Home
  2. DBL vs CDXS Comparison

DBL vs CDXS Comparison

Compare DBL & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DoubleLine Opportunistic Credit Fund of Beneficial Interest

DBL

DoubleLine Opportunistic Credit Fund of Beneficial Interest

HOLD

Current Price

$14.44

Market Cap

285.5M

Sector

N/A

ML Signal

HOLD

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$2.43

Market Cap

256.3M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
DBL
CDXS
Founded
2011
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
285.5M
256.3M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
DBL
CDXS
Price
$14.44
$2.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
45.5K
756.2K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
8.67%
N/A
EPS Growth
N/A
43.82
EPS
N/A
N/A
Revenue
N/A
$138,590,000.00
Revenue This Year
N/A
$7.73
Revenue Next Year
N/A
$14.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.30
52 Week Low
$14.08
$0.96
52 Week High
$16.01
$3.87

Technical Indicators

Market Signals
Indicator
DBL
CDXS
Relative Strength Index (RSI) 55.41 44.97
Support Level $14.13 $2.39
Resistance Level $14.59 $2.56
Average True Range (ATR) 0.10 0.15
MACD 0.01 -0.04
Stochastic Oscillator 64.80 16.52

Price Performance

Historical Comparison
DBL
CDXS

About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest

Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.

About CDXS Codexis Inc.

Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: